Pulmonary Nodule & Lung Cancer Screening

Patient: 58M, 30-pack-year smoker. CT chest for cough reveals incidental 14 mm solid RUL nodule with spiculated borders. No prior CT for comparison. No symptoms concerning for malignancy.

Key findings: High-risk features: > 8 mm, solid, spiculated margins, upper lobe location, smoker > 30 pack-years. Fleischner Society guidelines: solid nodule > 8 mm in high-risk patient → PET/CT or tissue sampling.

Management:

• PET/CT, FDG avidity suggests malignancy (SUV > 2.5 has ~90% sensitivity for malignant nodules > 8 mm)
• If PET-avid: CT-guided biopsy or navigational bronchoscopy for tissue diagnosis
• If biopsy confirms NSCLC: staging with brain MRI → surgical resection if early stage (lobectomy + mediastinal lymph node dissection)
• If PET-negative: CT surveillance at 3 months, then annually × 2-3 years (false negatives occur with low-grade adenocarcinoma)
• Low-dose CT lung cancer screening annually (meets USPSTF criteria: age 50-80, ≥ 20 pack-years)

Teaching point: Spiculated margins are the single most concerning morphologic feature for malignancy (~90% PPV). Smooth, well-defined margins favor benign, but do not rule out cancer. Size + morphology + risk factors together determine the approach.

Patient: 45F never-smoker. CT PE study (negative for PE) incidentally shows a 6 mm pure ground-glass nodule (GGN) in the LLL. No solid component. No prior imaging.

Key findings: Pure GGN 6 mm, these are almost always preinvasive adenocarcinoma (AIS/MIA) or atypical adenomatous hyperplasia if persistent. Very slow-growing, doubling time often > 800 days. Low risk of metastasis even if malignant.

Management:

• Fleischner 2017: 6 mm pure GGN → follow-up CT at 6-12 months to confirm persistence
• If persistent: CT annually × 5 years (these grow very slowly, long surveillance needed)
• No PET/CT (pure GGNs are often PET-negative even if malignant, low metabolic activity)
• No biopsy unless growing or developing solid component
• If develops solid component (> 5 mm solid): reclassify as part-solid → more aggressive workup

Teaching point: Pure GGNs are indolent, even when malignant (AIS/MIA), they rarely metastasize. The danger is the development of a solid component, which transforms the prognosis. Part-solid nodules with solid component > 5 mm have the highest malignancy risk of all nodule types.

Patient: 62M, 35-pack-year smoker. Annual LDCT screening shows 3 new nodules: 4 mm solid RML, 7 mm solid RUL, and 9 mm part-solid LUL (6 mm solid component). No prior nodules.

Key findings: Multiple nodules with one dominant suspicious nodule (9 mm part-solid with 6 mm solid component). Lung-RADS 4B. The part-solid nodule with substantial solid component is the most concerning, warrants tissue diagnosis.

Management:

• Dominant nodule (9 mm part-solid): PET/CT → if avid, navigational bronchoscopy or CT-guided biopsy
• 4 mm solid: Fleischner → follow-up CT at 12 months (low risk at this size)
• 7 mm solid: short-interval CT at 3 months or PET/CT given smoking history
• If dominant nodule = cancer: full staging → may need PET/CT of all nodules (separate primaries vs metastases)
• Continue annual LDCT screening regardless of this finding

Teaching point: With multiple nodules, manage based on the most suspicious nodule. Part-solid nodules with solid component ≥ 6 mm have the highest malignancy risk (~60%). Multiple nodules in a smoker are more likely separate primary lung cancers than metastases from a single primary.